STOCK TITAN

Scisparc - SPRC STOCK NEWS

Welcome to our dedicated page for Scisparc news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on Scisparc stock.

SciSparc Ltd. (SPRC) is a clinical-stage pharmaceutical innovator developing cannabinoid-based therapies for neurological disorders while operating a consumer hemp products division. This page provides verified updates on both business segments, serving investors and stakeholders with essential news repository.

Access authoritative information on SPRC's clinical trial advancements, regulatory filings, and financial performance alongside developments in its hemp-derived product line. Content includes press releases detailing research milestones, partnership announcements, and strategic initiatives across therapeutic and consumer markets.

Key updates cover FDA communications, intellectual property developments, quarterly earnings disclosures, and operational expansions. All materials are curated to meet investor needs for decision-making clarity while maintaining compliance with financial reporting standards.

Bookmark this resource for streamlined access to SPRC's official announcements and analysis. Regularly updated content ensures stakeholders stay informed about the company's progress in pharmaceutical innovation and consumer market execution.

Rhea-AI Summary

SciSparc (Nasdaq: SPRC), a clinical-stage pharmaceutical company, has received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement. The company's stock must maintain a minimum bid price of $1.00 per share to remain listed. SciSparc has been granted a 180-day grace period, until January 13, 2025, to regain compliance.

To comply, the closing bid price of SPRC shares must be at least $1.00 for a minimum of ten consecutive business days. If unsuccessful, the company may be eligible for an additional 180-day compliance period. Failure to meet requirements could result in delisting from Nasdaq. The notice does not immediately affect SciSparc's listing or trading of its ordinary shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
none
-
Rhea-AI Summary

SciSparc (Nasdaq: SPRC) has announced the submission of a new patent application to the USPTO for a novel composition combining Palmitoylethanolamide (PEA), the active ingredient in their CannAmide™ product, with Clearmind Medicine's MEAI compound. This innovative formulation aims to treat metabolic syndrome and obesity.

The patent application is part of an ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) and was developed in conjunction with Professor Joseph Tam from the Hebrew University. This marks the thirteenth patent application filed under this partnership, targeting various disorders including alcohol use disorder and cocaine addiction.

The obesity treatment market, valued at $15 billion in 2022, is expected to grow at a 10.0% CAGR. With obesity affecting 41.9% of U.S. adults aged 20 and over, this new treatment could address a significant health concern and market opportunity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
none
-
Rhea-AI Summary

SciSparc announced signing a non-binding letter of intent (LOI) to spin off its advanced clinical-stage pharmaceutical portfolio and equity stake in SciSparc Nutraceuticals to Miza III Ventures. Valued at $11.6 million, the assets will be exchanged for 63.3 million Miza shares and up to 48 million contingent rights. The deal's final terms will determine SciSparc's controlling stake in Miza, estimated between 75% and 84.53%. The transaction aligns with SciSparc's strategy to enhance shareholder value and follows a merger agreement with AutoMax Motors. Key portfolio assets include SCI-110 for Tourette syndrome and Alzheimer's disease, and SCI-210 for autism.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
none
Rhea-AI Summary

SciSparc (Nasdaq: SPRC), a clinical-stage pharmaceutical company, announced the European Patent Office granted its patent application for 'Compositions and Methods of Potentiating Antimicrobials'. This patent, which complements a similar U.S. patent, enhances SciSparc's intellectual property portfolio and competitive edge in the pharmaceutical industry. The patent covers pharmaceutical compositions combining antibiotics and cannabinoids, potentially addressing antimicrobial resistance. SciSparc is actively expanding its intellectual property globally, with recent patents in Canada and Europe, reflecting its commitment to innovation. The company’s portfolio now spans major markets including the U.S., Europe, Japan, Australia, and Israel, encompassing nine patent families and two trademarks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.43%
Tags
none
-
News
Rhea-AI Summary
SciSparc (Nasdaq: SPRC) announces a merger agreement with AutoMax Motors , a leading vehicle importer in Israel. The deal entails SciSparc acquiring 100% of AutoMax, forming a new Israeli subsidiary. Shareholders will hold 50.01% of the Combined Company post-merger. The Acquisition aims to maximize shareholder value following a strategic review in 2022. The deal is subject to regulatory approvals and shareholder agreement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
-
Rhea-AI Summary
SciSparc announces collaboration with Clearmind Medicine Inc. for novel therapy to treat depression. Clearmind submits patent application for MEAI compound combined with SciSparc's CannAmide™. Global depression and anxiety disorders treatment market expected to reach USD 41.83 billion by 2034.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.45%
Tags
none
Rhea-AI Summary
SciSparc announces MitoCareX Bio's successful identification of potential anti-cancer small molecules through advanced drug discovery platform and in-vitro screening systems, leading to the development of a predictive AI model for more efficient drug discovery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
none
-
Rhea-AI Summary
SciSparc (Nasdaq: SPRC) secures a patent for its core technology combining cannabinoids and n-acylethanolamines from the Canadian Intellectual Property Office. The patent aims to enhance the safety of cannabinoids with low dosages while maintaining therapeutic benefits, supporting the company's innovative technologies for central nervous system disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.1%
Tags
none
-
Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) has dosed the first patient in a clinical trial for Autism Spectrum Disorder in pediatric patients. The trial is for SCI-210 at Soroka Medical Center, marking a crucial advancement in treating rare diseases of the central nervous system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) announces MitoCareX Bio's progress in utilizing a predictive AI model to identify potential anti-cancer treatments. MitoCareX screened millions of small molecules, confirming anti-cancer activity through in-vitro testing. The company aims to enhance drug discovery efficiency by developing a predictive AI model.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.78%
Tags
none
Scisparc

Nasdaq:SPRC

SPRC Rankings

SPRC Stock Data

3.06M
10.83M
0%
1.21%
0.62%
Biotechnology
Healthcare
Link
Israel
Tel Aviv